- FDA Approves First and Only Therapy for IgG4-RD Medscape
- US FDA approves Amgen’s Uplizna as first treatment for rare immune disorder Reuters
- Amgen wins key rare disease nod for Uplizna, checking off one goal in expansion push Fierce Pharma
- FDA approves Amgen’s Uplizna in IgG4-related disease Endpoints News
- Amgen’s Uplizna wins first FDA approval for rare inflammatory disease FirstWord Pharma